1. All Products
  2. D - Drugs
  3. VACCINE MENINGITIS ACYWX ps. CONJ., 1 dose, multidose, vial
Public Pricelist

VACCINE MENINGITIS ACYWX ps. CONJ., 1 dose, multidose, vial

https://medicalguidelines.msf.org/en/node/272
https://unicat.msf.org/cat/product/93533
STD DVACVMENX1VD

Valid Article

The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
19.3 - Vaccines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J07AH05
Anatomical Therapeutic Chemical Classification according to WHOCC
0208
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

See Related

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

VACCINE MENINGITIS polysac. CONJ. ACYWX

CAUTION

This multidose vaccine is worded and codified by unit (= 1 dose) to make the order easier.

Full Name

MenFive 5µg®

Therapeutic Action

Freeze-dried vaccine inducing the production of bactericidal antibodies specific to the capsular polysaccharides of Neisseria meningitidis serogroups A, C, Y, W-135 and X.

Indications

Active immunisation against meningitis due to Neisseria meningitidis groups A, C, Y, W and X in children from 1 year of age, adolescents and adults at risk of invasive disease.

The meningococcal ACYWX conjugate vaccine (MenFive®) is indicated in:

  • preventive vaccination mass campaigns in individuals aged 1 to 19 years or 2 to 19 years of age, depending on the age group targeted by the routine immunisation programme.
  • reactive vaccination campaigns in individuals aged from 9 months to 29 years.

All countries in the meningitis belt should introduce the MenFive®vaccine into their routine immunisation programme.

The countries that have already introduced a monovalent meningococcal A conjugate vaccine into their routine programme should switch to MenFive® vaccine.

Instructions for use

Reconstitute the powder vial with the diluent supplied by the manufacturer.

1 dose = 0.5 ml reconstituted suspension = 5 µg of each Meningococcal A, C, Y, W, and X polysaccharide.

Must be given as IM injection into the anterolateral part of the thigh in children < 5 years or into the deltoid muscle in children ≥ 5 years and adults.

Do not forget to order the diluent together with the vaccine!

Orders are always done in number of doses and not in number of vials! (See Preliminary remarks on Vaccines)

Precautions for Use

As with all injectable vaccines and/or immunoglobulins, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the product.

Storage

  • Do not freeze.
  • Powder: between 2°C and 8°C - Protect from sunlight
  • Diluent: cold chain is not required for storage. However, at least 12 hrs before reconstitution of the vaccine, the diluent must be refrigerated between 2ºC and 8ºC so that the diluent and lyophilised powder are at the same temperature (a thermic shock during reconstitution could reduce the vaccine efficacy).
  • Vaccine reconstituted: between 2°C and 8°C for 6 hrs maximum, protected from the light.
  • The vaccine vial monitor (VVM) is mandatory on each vaccine.

(Cf Introduction: Thermosensitive products)